BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22298798)

  • 1. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting.
    Jaitner J; Morath T; Byrne RA; Braun S; Gebhard D; Bernlochner I; Schulz S; Mehilli J; Schömig A; Koch W; Kastrati A; Sibbing D
    Circ Cardiovasc Interv; 2012 Feb; 5(1):82-8, S1-2. PubMed ID: 22298798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes.
    Spiewak M; Małek ŁA; Kostrzewa G; Kisiel B; Serafin A; Filipiak KJ; Płoski R; Opolski G
    Kardiol Pol; 2009 Aug; 67(8):827-34. PubMed ID: 19784880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis.
    Luo M; Li J; Xu X; Sun X; Sheng W
    Thromb Res; 2012 Jun; 129(6):754-9. PubMed ID: 22209339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
    Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
    Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
    Tavassoli N; Voisin S; Carrie D; Lapeyre-Mestre M; Galinier M; Montastruc JL; Pathak A
    Am J Cardiovasc Drugs; 2010; 10(1):29-35. PubMed ID: 20104932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
    Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
    Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of P-glycoprotein on clopidogrel absorption.
    Taubert D; von Beckerath N; Grimberg G; Lazar A; Jung N; Goeser T; Kastrati A; Schömig A; Schömig E
    Clin Pharmacol Ther; 2006 Nov; 80(5):486-501. PubMed ID: 17112805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stent thrombosis is associated with an impaired response to antiplatelet therapy.
    Wenaweser P; Dörffler-Melly J; Imboden K; Windecker S; Togni M; Meier B; Haeberli A; Hess OM
    J Am Coll Cardiol; 2005 Jun; 45(11):1748-52. PubMed ID: 15936599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epistaxis as the reason for premature discontinuation of clopidogrel after percutaneous coronary angioplasty with stent implantation.
    Jura-Szołtys E; Chudek J
    Kardiol Pol; 2011; 69(8):817-23. PubMed ID: 21850627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
    Sarafoff N; Sibbing D; Sonntag U; Ellert J; Schulz S; Byrne RA; Mehilli J; Schömig A; Kastrati A
    Thromb Haemost; 2010 Sep; 104(3):626-32. PubMed ID: 20664905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.
    Han YL; Wang B; Li Y; Xu K; Wang SL; Jing QM; Wang ZL; Wang DM; Ma YY; Wang G
    Chin Med J (Engl); 2009 Apr; 122(7):793-7. PubMed ID: 19493391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents.
    Lemesle G; Torguson R; Bonello L; de Labriolle A; Maluenda G; Ben-Dor I; Collins SD; Syed AI; Xue Z; Satler LF; Pichard AD; Waksman R
    EuroIntervention; 2011 Apr; 6(9):1053-9. PubMed ID: 21518676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
    J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.